Table 1.
Baseline characteristics by treatment group for patients with limited-stage small-cell lung cancer.
| Characteristics | Overall (N = 113) | IO + CT (N = 34) | IO + RT + CT (N = 26) | RT + CT (N = 53) | p |
|---|---|---|---|---|---|
| Sex (%) | 0.447 | ||||
| Female | 30 (26.5) | 7 (20.6) | 6 (23.1) | 17 (32.1) | |
| Male | 83 (73.5) | 27 (79.4) | 20 (76.9) | 36 (67.9) | |
| Smoke (%) | 0.728 | ||||
| Former/current | 76 (67.3) | 23 (67.6) | 19 (73.1) | 34 (64.2) | |
| Never/unknown | 37 (32.7) | 11 (32.4) | 7 (26.9) | 19 (35.8) | |
| ECOG (%) | 0.872 | ||||
| PS0-1 | 110 (97.3) | 33 (97.1) | 25 (96.2) | 52 (98.1) | |
| PS2 | 3 (2.7) | 1 (2.9) | 1 (3.8) | 1 (1.9) | |
| T (%) | 0.576 | ||||
| T1 | 10 (8.8) | 3 (8.8) | 2 (7.7) | 5 (9.4) | |
| T2 | 41 (36.3) | 13 (38.2) | 13 (50.0) | 15 (28.3) | |
| T3 | 25 (22.1) | 6 (17.6) | 6 (23.1) | 13 (24.5) | |
| T4 | 37 (32.7) | 12 (35.3) | 5 (19.2) | 20 (37.7) | |
| N (%) | 0.242 | ||||
| N0 | 8 (7.1) | 1 (2.9) | 1 (3.8) | 6 (11.3) | |
| N1 | 16 (14.2) | 5 (14.7) | 2 (7.7) | 9 (17.0) | |
| N2 | 70 (61.9) | 23 (67.6) | 15 (57.7) | 32 (60.4) | |
| N3 | 19 (16.8) | 5 (14.7) | 8 (30.8) | 6 (11.3) | |
| TNM (%) | 0.115 | ||||
| I–II | 16 (14.2) | 4 (11.8) | 1 (3.8) | 11 (20.8) | |
| III | 97 (85.8) | 30 (88.2) | 25 (96.2) | 42 (79.2) | |
| PCI (%) | 6 (5.3) | 2 (5.9) | 1 (3.8) | 3 (5.7) | 0.930 |
| Age (median (IQR)) | 64.0 (57.0, 68.0) | 64.0 (56.0, 66.0) | 61.0 (56.2, 66.8) | 65.0 (58.0, 69.0) | 0.299 |
| BMI (median (IQR)) | 25.4 (23.6, 27.0) | 25.2 (24.2, 27.8) | 25.4 (22.6, 26.1) | 25.7 (23.6, 27.0) | 0.567 |
| ALB (median (IQR)) | 41.2 (38.1, 42.7) | 41.2 (38.7, 42.6) | 41.0 (38.8, 42.7) | 40.9 (38.0, 42.8) | 0.954 |
| LDH (median (IQR)) | 173.0 (153.0, 205.0) | 162.0 (151.0, 177.0) | 184.5 (154.5, 205.0) | 183.0 (158.0, 208.0) | 0.142 |
| CRP (median (IQR)) | 3.6 (1.2, 9.5) | 4.2 (1.3, 10.0) | 4.6 (1.7, 11.1) | 3.4 (1.1, 6.9) | 0.604 |
| NLR (median (IQR)) | 2.3 (1.7, 3.3) | 2.4 (1.6, 3.6) | 2.2 (1.8, 2.9) | 2.4 (1.8, 3.3) | 0.972 |
| SII (median (IQR)) | 566.0 (376.0, 779.0) | 569.5 (344.0, 732.8) | 562.0 (471.0, 735.2) | 560.0 (376.0, 841.0) | 0.658 |
| dNLR (median (IQR)) | 1.7 (1.3, 2.2) | 1.8 (1.1, 2.4) | 1.7 (1.4, 1.9) | 1.7 (1.3, 2.3) | 0.946 |
| NSE (median (IQR)) | 22.3 (15.1, 32.6) | 21.9 (14.1, 28.0) | 17.9 (13.3, 28.1) | 26.6 (17.2, 40.6) | 0.191 |
| pro-GRP (median (IQR)) | 549.5 (130.4, 1388.0) | 489.9 (101.8, 1306.9) | 860.7 (117.2, 2527.2) | 460.3 (153.2, 1373.6) | 0.559 |
ALB, albumin; BMI, body mass index; CRP, C-reactive protein; CT, chemotherapy; dNLR, derived neutrophil-to-lymphocyte ratio; ECOG PS, Eastern Cooperative Oncology Group performance status; IO, immunotherapy; IQR, Interquartile range; LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; NSE, neuron-specific enolase; PCI, prophylactic cranial irradiation; pro-GRP, progastrin-releasing peptide; RT, radiotherapy; SII, systemic inflammatory index.